1 min read
Biohaven Plans Pivotal Trial for Cancer Candidate BHV-1530 by 2027
The company announced early-stage trial data for the antibody-drug conjugate on Nov. 19.

Biohaven Ltd. (BHVN) shares rose Nov. 19 after the company announced early-stage trial data for cancer candidate BHV-1530 and plans to advance it to a pivotal trial as early as 2027.
BHV-1530 is an antibody-drug conjugate.